Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
Agile Therapeutics第四季度調整後美元（1.46美元）未達到預期（0.92美元），銷售額爲362萬美元，低於407萬美元的預期
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.92) by 58.7 percent. This is a 83.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported quarterly sales of $3.62 million which missed the analyst consensus estimate of $4.07 million by 11.18 percent. This is a 9.53 percent decrease over sales of $4.00 million the same period last year.
Agile Therapeutics（納斯達克股票代碼：AGRX）公佈的季度虧損爲每股1.46美元，比分析師普遍預期的0.92美元（0.92美元）低58.7％。這比去年同期每股虧損9.00美元（9.00）增長了83.78％。該公司公佈的季度銷售額爲362萬美元，比分析師普遍預期的407萬美元低11.18％。這比去年同期的400萬美元銷售額下降了9.53％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。